In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bluebird bio Inc.

www.bluebirdbio.com

Latest From bluebird bio Inc.

ElevateBio Announces AlloVir As First Spoke In Its Cell And Gene Therapy Hub

ElevateBio revealed the first company to hitch up with its newly established centralized cell and gene therapy development, manufacturing and commercial capabilities – AlloVir, formerly ViraCyte, which is developing T-cell therapies to treat viruses in immunocompromised patients.

Financing StartUps and SMEs

Gene Therapy In The Real World: Long-Term Follow Up Is Key – If Patients Are Willing

The first of what promises to be a wave of potentially curative gene therapies are coming to market. One of the challenges for sponsors will be how to deliver long-term outcomes data demanded by regulators and payors from patients who don’t have any reason to go to the doctor.

Gene Therapy Post Market Regulation & Studies

Where Is J&J Investing For The Future? Cell Therapy, Gene Therapy And RNA

Janssen global head of R&D Mathai Mammen said the three areas are therapeutic modalities J&J is prioritizing for future drug development, both internally and through partnering.

Gene Therapy ImmunoOncology

Bluebird Lays Some New Eggs, But They'll Take Time To Hatch

Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.

Gene Therapy ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • bluebird bio LLC
  • bluebird bio LLC
  • Genetix Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • bluebird bio Inc.
  • Senior Management
  • Nick Leschly, Pres. & CEO
    Chip Baird, CFO
    Philip Gregory, CSO
    David Davidson, MD, CMO
    Joanne Smith-Farrell, PhD, CBO
    Alison Finger, Chief Commercial Officer
  • Contact Info
  • bluebird bio Inc.
    Phone: (339) 499-9300
    60 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register